ReviewTrends in endocrinology and metabolism: TEM2021
Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.
Review in Trends in endocrinology and metabolism: TEM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 60 citations in OpenAlex.
- Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer.iScience · 2026Article
- Defining Cachexia in Children With Cancer in the United States: Developing a Framework to Inform Clinical and Research Practice.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2026Article
- Assessment of Muscle Function Decline and Cachexia-Related Biomarkers in Hospitalized Oncology Patients: Study Protocol.Biomedicines · 2026Article
- Longitudinal Changes in Body Composition and Fluid Distribution During Chemotherapy in Breast Cancer Patients: A Prospective Single-Center Longitudinal Observational Study Using Bioimpedance Spectroscopy.Journal of clinical medicine · 2026Article
- Review
- The clinical application value of body composition in predicting the prognosis of rectal cancer.International journal of clinical oncology · 2026Article
- Downregulation of Organ-Derived Activin A Attenuates Muscle Atrophy and Intramuscular Fat Infiltration in Cancer Cachexia Mice.Journal of cachexia, sarcopenia and muscle · 2026Article
- Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.Journal of advanced research · 2026Article
- Short-Term Biceps Muscle Wasting Assessed by Serial Ultrasound as a Predictor of Survival Duration in Terminally Ill Cancer Patients: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Exercise-modulated IL-6 in cancer cachexia: molecular mechanisms and therapeutic potential.Journal of translational medicine · 2026Review
- Early physiological phenotypes and survival outcomes in advanced non-small cell lung cancer: a longitudinal study of dynamic muscle loss and functional decline.Frontiers in oncology · 2026Article
- The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies.Medical oncology (Northwood, London, England) · 2025Review
- Neuromuscular Electrical Stimulation Plus Nutritional Counseling Attenuates Thigh Muscle Thickness Loss in Hospitalized Cancer Patients.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1.Nature communications · 2025Article
- Treatment barriers among patients with cancer cachexia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Clinical Evaluation of Patients Using Antineoplastic Chemotherapeutic Agents with Body Composition Monitor Measurement Before and at 3 Months of Treatment.Journal of clinical medicine · 2025Article
- The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis.Current oncology (Toronto, Ont.) · 2025Review
- Alpha-Ketoisocaproate Attenuates Muscle Atrophy in Cancer Cachexia Models.Journal of cachexia, sarcopenia and muscle · 2025Article
- Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development.Molecular cancer · 2025Review
- SIRT6 Ameliorates Cancer Cachexia-Associated Adipose Wasting by Suppressing TNFR2 Signalling in Mice.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Muscle cachexia has a major detrimental impact on cancer patients, being responsible for 30% of all cancer deaths. It is characterized by a debilitating loss in muscle mass and function, which ultimately deteriorates patients' quality of life and dampens therapeutic treatment efficacy. Muscle cachexia stems from widespread alterations in whole-body metabolism as well as immunity and neuroendocrine functions and these global defects often culminate in aberrant signaling within skeletal muscle, causing muscle protein breakdown and attendant muscle atrophy. This review summarizes recent landmark discoveries that significantly enhance our understanding of the molecular etiology of cancer-driven muscle cachexia and further discuss emerging therapeutic approaches seeking to simultaneously target those newly discovered mechanisms to efficiently curb this lethal syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.